Ozempic, Wegovy Users Sue Over Rare ‘Eye Stroke’ Vision Loss

The rapid rise of blockbuster weight-loss and diabetes medications has transformed modern medicine, but a growing wave of legal challenges is now casting a shadow over their safety profiles. Hundreds of patients who took popular GLP-1 drugs like Ozempic and Wegovy are taking legal action, claiming the treatments caused them to suffer sudden, irreversible vision loss. At the heart of the litigation is a rare condition known as an "eye stroke," which plaintiffs argue should have been clearly disclosed on the drugs' warning labels.

What Happened

Dozens of civil lawsuits have been filed against major pharmaceutical companies, including Novo Nordisk, the maker of Ozempic and Wegovy, and Eli Lilly, the maker of Zepbound and Mounjaro. The lawsuits allege that these popular GLP-1 receptor agonists are linked to non-arteritic anterior ischemic optic neuropathy (NAION).

NAION is a rare but severe eye condition that occurs when blood flow to the optic nerve is suddenly blocked or reduced, causing rapid and often permanent vision loss. Because of how the condition cuts off blood flow, medical professionals frequently refer to it as an "eye stroke". Plaintiffs in these lawsuits claim that the drug manufacturers knew or should have known about the potential link between semaglutide (the active ingredient in Ozempic and Wegovy) and optic nerve damage, but failed to provide adequate warnings to doctors and patients in the United States.

• Hundreds of lawsuits: Patients across the country have filed legal claims, with many cases being consolidated in federal court to streamline the litigation process.
• The "Eye Stroke" condition: NAION causes sudden, painless vision loss in one or both eyes, and there is currently no approved medical treatment to reverse the damage.
• Harvard study findings: A landmark 2024 study published in JAMA Ophthalmology found that patients prescribed semaglutide had a significantly higher relative risk of developing NAION compared to those on other medications.
• Labeling discrepancies: While NAION is not listed on GLP-1 warning labels in the U.S., Novo Nordisk updated its labels in Europe to warn that semaglutide may cause NAION in up to 1 in 10,000 patients.
• Manufacturer responses: Novo Nordisk has stated that the lawsuits are "without merit" and vows to fight them vigorously, while Eli Lilly maintains that patient safety is its top priority.

Why It Matters

For millions of Americans, GLP-1 medications have been a life-changing tool for managing type 2 diabetes and achieving significant weight loss. However, the emergence of severe, irreversible side effects like permanent blindness raises critical questions about the balance between a drug's benefits and its risks.

Because NAION has no known cure, patients who develop the condition face life-altering consequences, including the loss of their livelihoods, independence, and quality of life. The litigation highlights a broader systemic issue: how quickly safety signals are identified, evaluated, and communicated to the public once a drug explodes in popularity. If the lawsuits succeed, they could force pharmaceutical companies to implement stricter warning labels in the U.S., altering how doctors prescribe these highly sought-after medications.

What Happens Next

The legal battle is expected to intensify as more plaintiffs join the litigation. In the U.S., dozens of these lawsuits have already been consolidated in federal court, allowing attorneys to begin the discovery phase to examine what the manufacturers knew about the vision risks and when they knew it.

Meanwhile, the medical community is continuing to investigate the correlation. The U.S. Food and Drug Administration (FDA) has stated that it is still actively evaluating the safety signals and has not yet issued an official safety warning or mandated a label change in the United States. Researchers are calling for larger, long-term clinical trials to definitively establish whether GLP-1 drugs directly cause optic nerve damage or if other underlying health factors, such as diabetes itself, are the primary drivers.

What We Still Don't Know

1. Does semaglutide directly cause the blood flow blockages that lead to NAION, or is the correlation driven by underlying health conditions like diabetes and obesity?
2. Will the FDA mandate that U.S. manufacturers update their warning labels to include the risk of "eye strokes," similar to the label updates already implemented in Europe?
3. How will the outcome of these consolidated lawsuits affect the future availability, pricing, and prescribing guidelines of GLP-1 medications in the United States?

Source Note

This story draws on reporting from Fox News.